Disease, treatment, and outcome differences between men and women with follicular lymphoma in the United States

Chadi Nabhan, Xiaolei Zhou, Bann Mo Day, Keith Dawson, Andrew D. Zelenetz, Jonathan W. Friedberg, James R. Cerhan, Brian K. Link, Christopher R. Flowers

Research output: Contribution to journalArticlepeer-review

12 Scopus citations

Abstract

We aimed to comprehensively study sex differences in disease and patients' characteristics, treatment and outcomes in patients with follicular lymphoma (FL) in the United States (USA) utilizing the National LymphoCare Study registry (2004–2014). Among evaluable males (n = 1277) and females (n = 1375) with FL, females less commonly received anthracyclines and were more likely to receive rituximab monotherapy. Overall response rates were comparable between sex groups. With a median follow-up of 8.1 years, male sex emerged as an adverse factor for PFS (HR, 0.84, 95% CI, 0.72–0.97). Lymphoma-related mortality (HR, 0.46; 0.23–0.93) and overall survival (HR, 0.63; 0.41–0.97) favored females aged ≤60 years. There are subtle differences in outcomes between male and female FL patients diagnosed and treated in the contemporary era. These data represent the largest prospective analysis of FL patients in the USA based on sex and can aid design of clinical trials for this disease. Am. J. Hematol. 91:770–775, 2016.

Original languageEnglish (US)
Pages (from-to)770-775
Number of pages6
JournalAmerican journal of hematology
Volume91
Issue number8
DOIs
StatePublished - Aug 1 2016

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Disease, treatment, and outcome differences between men and women with follicular lymphoma in the United States'. Together they form a unique fingerprint.

Cite this